Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report) shares fell 8% during trading on Tuesday . The stock traded as low as $7.41 and last traded at $7.41. 2,050 shares were traded during trading, an increase of 42% from the average session volume of 1,447 shares. The stock had previously closed at $8.05.
Nxera Pharma Stock Performance
The firm’s fifty day moving average price is $8.14 and its 200-day moving average price is $9.07.
About Nxera Pharma
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.
Featured Stories
- Five stocks we like better than Nxera Pharma
- Market Cap Calculator: How to Calculate Market Cap
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Netflix Is On Track To Hit $1,000 By Christmas
- Low PE Growth Stocks: Unlocking Investment Opportunities
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
